OmniAb Inc. (NASDAQ:OABI) — Market Cap & Net Worth
Market Cap & Net Worth: OmniAb Inc. (OABI)
OmniAb Inc. (NASDAQ:OABI) has a market capitalization of $574.29 Million ($574.29 Million) as of September 26, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #11633 globally and #2957 in its home market, demonstrating a 3.83% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying OmniAb Inc.'s stock price $4.61 by its total outstanding shares 145390398 (145.39 Million). Also see OABI asset base for a full breakdown of the balance sheet.
OmniAb Inc. Market Cap History: 2021 to 2026
OmniAb Inc.'s market capitalization history from 2021 to 2026. Data shows change from $1.45 Billion to $670.25 Million (-13.96% CAGR). Also see OmniAb Inc. (OABI) cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
OmniAb Inc. is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.64 Trillion | 0.02% | #315 of 976 |
|
NASDAQ Composite
IXIC
|
$42.21 Trillion | 0.00% | #1166 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.87 Trillion | 0.03% | #178 of 263 |
Weight: OmniAb Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
OmniAb Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how OmniAb Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check today's stock price for OmniAb Inc. for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
14.41x
OmniAb Inc.'s market cap is 14.41 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.45 Billion | $34.75 Million | -$27.04 Million | 41.84x | N/A |
| 2022 | $523.41 Million | $59.08 Million | -$22.33 Million | 8.86x | N/A |
| 2023 | $897.06 Million | $34.16 Million | -$50.62 Million | 26.26x | N/A |
| 2024 | $514.68 Million | $26.39 Million | -$62.03 Million | 19.50x | N/A |
| 2025 | $268.97 Million | $18.67 Million | -$64.78 Million | 14.41x | N/A |
Competitor Companies of OABI by Market Capitalization
Companies near OmniAb Inc. in the global market cap rankings as of September 26, 2026. Review OmniAb Inc. tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to OmniAb Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #339 globally with a market cap of $79.70 Billion USD.
- CSL Ltd (AU:CSL): Ranked #453 globally with a market cap of $60.74 Billion USD ( AU$85.85 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #507 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $526.19 |
| #339 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.70 Billion | $788.04 |
| #453 | CSL Ltd | AU:CSL | $60.74 Billion | AU$176.95 |
| #507 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $198.88 |
OmniAb Inc. Historical Marketcap From 2021 to 2026
Between 2021 and today, OmniAb Inc.'s market cap moved from $1.45 Billion to $ 670.25 Million, with a yearly change of -13.96%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $670.25 Million | +149.19% |
| 2025 | $268.97 Million | -47.74% |
| 2024 | $514.68 Million | -42.63% |
| 2023 | $897.06 Million | +71.39% |
| 2022 | $523.41 Million | -64.00% |
| 2021 | $1.45 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 26th, 2026 the market cap of OmniAb Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $574.29 Million USD |
| MoneyControl | $574.29 Million USD |
| MarketWatch | $574.29 Million USD |
| marketcap.company | $574.29 Million USD |
| Reuters | $574.29 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About OmniAb Inc.
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partne… Read more